

ENHANCED SPECIALTY GUIDELINE MANAGEMENT

REPATHA (evolocumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met, and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

- A. Repatha is indicated in adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization.
- B. Repatha is indicated as an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C.
- C. Repatha is indicated as an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C.
- D. Repatha is indicated as an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C.

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

A. Clinical atherosclerotic cardiovascular disease (ASCVD)

Authorization of 6 months may be granted for treatment of clinical atherosclerotic cardiovascular disease when both of the following criteria are met:

1. Documentation that the member has a history of clinical ASCVD (See Appendix A).
2. Documentation that the member meets at least one of the following criteria:
 - a. Member has a current LDL-C level ≥ 70 mg/dL after at least three months of treatment with a high-intensity statin dose in combination with ezetimibe. If the member is unable to tolerate a high-intensity statin dose, a moderate-intensity statin dose may be used.
 - b. Member has a current LDL-C level ≥ 70 mg/dL with contraindication or intolerance to statins (See Appendix B and C).

B. Primary hyperlipidemia

Authorization of 6 months may be granted for treatment of primary hyperlipidemia when both of the following criteria are met:

1. Documentation that the member had an untreated (before any lipid lowering therapy) LDL-C level ≥ 190 mg/dL in the absence of a secondary cause.
2. Documentation that the member meets at least one of the following criteria:
 - a. Member has a current LDL-C level ≥ 100 mg/dL after at least three months of treatment with a high-intensity statin dose in combination with ezetimibe. If the member is unable to tolerate a high-intensity statin dose, a moderate-intensity statin dose may be used.
 - b. Member has a current LDL-C level ≥ 100 mg/dL with a contraindication or intolerance to statins (See Appendix B and C).

Effective Date: 9/2017
Reviewed: 12/2018, 9/2019, 6/2020, 3/2021, 3/2023, 6/2024, 7/2025 Scope: Medicaid

C. Heterozygous familial hypercholesterolemia (HeFH)

Authorization of 6 months may be granted for treatment of heterozygous familial hypercholesterolemia when both of the following criteria are met:

1. Documentation that the member meets either of the following criteria:
 - a. Member is 18 years of age or older and had an untreated (before any lipid lowering therapy) LDL-C level ≥ 190 mg/dL in the absence of a secondary cause.
 - b. Member is less than 18 years of age and had an untreated (before any lipid lowering therapy) LDL-C level ≥ 160 mg/dL in the absence of a secondary cause.
2. Documentation that the member meets at least one of the following criteria:
 - a. Member has a current LDL-C level ≥ 100 mg/dL after at least three months of treatment with a high-intensity statin dose in combination with ezetimibe. If the member is unable to tolerate a high-intensity statin dose, a moderate-intensity statin dose may be used.
 - b. Member has a current LDL-C level ≥ 100 mg/dL with a contraindication or intolerance to statins (See Appendix B and C).

D. Homozygous familial hypercholesterolemia (HoFH)

Authorization of 6 months may be granted for treatment of homozygous familial hypercholesterolemia when both of the following criteria are met:

1. Documentation that the member meets either of the following criteria:
 - a. Member is 18 years of age or older and had an untreated (before any lipid lowering therapy) LDL-C level ≥ 190 mg/dL in the absence of a secondary cause.
 - b. Member is less than 18 years of age and had an untreated (before any lipid lowering therapy) LDL-C level ≥ 160 mg/dL in the absence of a secondary cause.
2. Documentation that the member meets at least one of the following criteria:
 - a. Member has a current LDL-C level ≥ 100 mg/dL after at least three months of treatment with a high-intensity statin dose in combination with ezetimibe. If the member is unable to tolerate a high-intensity statin dose, a moderate-intensity statin dose may be used.
 - b. Member has a current LDL-C level ≥ 100 mg/dL with a contraindication or intolerance to statins (See Appendix B and C).
3. Documentation that the member's dose does not exceed FDA approved labeling

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section III who achieve or maintain a documented LDL-C reduction (e.g., LDL-C is now at goal, robust lowering of LDL-C) and the member's dose does not exceed FDA approved labeling.

IV. QUANTITY LIMITS

Repatha 140mg/ml: 2 syringes or pens (2ml) per 28 days [daily dose of 0.08]

Repatha Push 420mg/3.5ml: 1 cartridge (3.5ml) per 28 days [daily dose of 0.13], with post-limit exception of 2 cartridges (7.5ml) per 28 days [daily dose of 0.27] for HoFH if a clinically meaningful response is not achieved in 12 weeks with 420mg once monthly dose or if member is receiving concomitant lipid apheresis

V. DOSING

Indication	Dosing
Adults with established cardiovascular disease or with primary hyperlipidemia	Repatha 140 mg every 2 weeks OR 420 mg once monthly administered subcutaneously
Pediatric patients aged 10 years and older with HeFH:	Repatha 140 mg every 2 weeks OR 420 mg once monthly administered subcutaneously
Adults and pediatric patients aged 10 years and older with HoFH	- Repatha 420 mg once monthly administered subcutaneously - The dosage can be increased to 420 mg every 2 weeks if a clinically meaningful response is not achieved in 12 weeks. - Patients on lipid apheresis may initiate treatment with 420 mg every 2 weeks to correspond with their apheresis schedule. Administer Repatha after the apheresis session is complete.

VI. APPENDICES

APPENDIX A. Clinical ASCVD

- Acute coronary syndromes
- Myocardial infarction
- Stable or unstable angina
- Coronary or other arterial revascularization procedure (e.g., percutaneous coronary intervention [PCI], coronary artery bypass graft [CABG] surgery)
- Stroke of presumed atherosclerotic origin
- Transient ischemic attack (TIA)
- Non-cardiac peripheral arterial disease of presumed atherosclerotic origin (e.g., carotid artery stenosis, lower extremity PAD)
- Obstructive coronary artery disease (defined as fifty percent or greater stenosis on cardiac computed tomography angiogram or catheterization)
- Coronary Artery Calcium (CAC) Score ≥ 1000

APPENDIX B. Statin-associated muscle symptoms (SAMS) and statin re-challenge

- Score of 7 or higher on the Statin-Associated Muscle Symptom Clinical Index (SAMS-CI)
 - Statin-associated elevation in creatine kinase (CK) level ≥ 10 times upper limit of normal (ULN)
- NOTE:** Statin re-challenge is NOT required for members who have experienced an elevation of CK level ≥ 10 times ULN after receiving lipid-lowering therapy (LLT) with a statin.

APPENDIX C. Contraindications to statins

- Active liver disease, including unexplained persistent elevations in hepatic transaminase levels (e.g., alanine transaminase (ALT) level ≥ 3 times ULN)
- Pregnancy or planned pregnancy
- Breastfeeding

VII. REFERENCES

1. Repatha [package insert]. Thousand Oaks, CA: Amgen, Inc.; May 2025. Accessed June 2025.

Effective Date: 9/2017
Reviewed: 12/2018, 9/2019, 6/2020, 3/2021, 3/2023, 6/2024, 7/2025
Scope: Medicaid

2. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused Update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. 2017;70:1785-822.
3. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387-97.
4. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 — full report. *J Clin Lipidol*. 2015;9:129–169.
5. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. *Eur Heart J*. 2013;34:3478–3490.
6. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *Eur Heart J*. 2014;35:2146-2157.
7. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015;385:341-350.
8. Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. *Arch Med Sci*. 2015;11:1-23.
9. Sabatine MC, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017; Published online before print.
10. Hulten EA, Carbonaro S, Petrillo SP, et al. Prognostic value of cardiac computed tomography angiography. *J Am Coll Cardiol*. 2011;57(10):1237-1247.
11. Min JK, Labounty TM, Gomez MJ, et al. Incremental prognostic value of coronary computed tomographic angiography over coronary artery calcium score for risk prediction of major adverse cardiac events in asymptomatic diabetic individuals. *Atherosclerosis*. 2014;232(2):298-304.
12. Robinson, J. G., Rogers, W. J., Nedergaard, B. S., Fialkow, J., Neutel, J. M., Ramstad, D., Somaratne, R., Legg, J. C., Nelson, P., Scott, R., Wasserman, S. M. and Weiss, R. (2014), Rationale and Design of LAPLACE-2: A Phase 3, Randomized, Double-Blind, Placebo- and Ezetimibe-Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy. *Clin Cardiol*, 37: 195–203.
13. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. *J Intern Med*. 2009 May;265(5):568-80.
14. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol: report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018.
15. Beavers CJ, Kelly MS. Dyslipidemia. In: Murphy Je, Lee MW, eds. Pharmacotherapy Self-Assessment Program, 2019 Book 1. Cardiology. Lenexa, KS: American College of Clinical Pharmacy, 2019:41-42.
16. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, et al. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. *J Am Heart Assoc*. 2019; 8:e013225. DOI: 10.1161/JAHA.119.013225.